# Lupin (LUPIN) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/lupin

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,988.1
- Change: +0.01%
- As of: 2026-11-06
- 1D return: +0.01%
- 5D return: -1.14%
- 1M return: +2.64%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

LUPIN (₹1,988.10) is trading in a near-term consolidation phase within a broader weekly downtrend. The daily ADX of 27.97 indicates established but directionless momentum, corroborated by high-participation anomalies on November 4 and 6 that showed no clear directional bias. Price action has formed consecutive Doji candles, signaling indecision as the stock hovers between immediate support at ₹1,986.54 and resistance at ₹2,007.10.

While the monthly Supertrend remains bullish, the weekly and daily structures are bearish, with price below key moving averages (EMA 20/50, SMA 50/200) and the Supertrend on those timeframes. The stock is positioned near the lower end of its 252-day range (+15.0%) and sits in a significant drawdown (-20.9%). A break above ₹2,007 could signal a short-term relief rally toward ₹2,026, whereas a close below ₹1,975.60 would likely reinforce the bearish weekly trend.

- Trend Divergence: Monthly structure is bullish (Supertrend up), while weekly and daily trends are bearish (price below SMAs/EMAs and Supertrend).
- Momentum & Participation: Daily ADX is 27.97 (established strength), but recent anomalies show high volume with no clear direction, indicating a battle between buyers and sellers.
- Key Levels: Immediate support at ₹1,986.54; pivot support at ₹1,975.60. Resistance at ₹2,007.10 (0.96% above) and ₹2,026.20 (1.92% above).
- Risk Context: Stock is down -20.9% from available highs with annualized volatility of +23.7%. Current position is near the lower end of the yearly range (+15.0%).

- Doji
- Shooting Star
- Bearish Engulfing Reversal
- Hammer
- Harami

### News Context

Lupin reported Q2 FY27 results on November 4, posting revenue of ₹7,827.26 crore and net profit of ₹1,155.3 crore. While top-line figures marginally beat market estimates, profitability declined 22% year-on-year as EBITDA margins contracted to 26.1%. The company’s US business, its largest segment contributing 39% of sales, generated $317 million in revenue, exceeding expectations, while domestic sales grew 14.7% year-on-year. Following these results, shares closed 0.97% higher.

In the same week, brokerages maintained an 'Accumulate' rating with a target price of ₹2,250. PL Capital cited expected declines in Profit After Tax (PAT) over FY26-28E and increased competition for key products, cutting FY28E and FY29E EPS estimates by 2-5% due to the wearing away of peak margin benefits. This outlook contrasts with broader sector strength, as India’s pharmaceutical sector led equity gains in 2026 with a 27% year-to-date rise in its index, driven by resilient domestic demand and improving US margins.

- Q2 FY27 financials: Revenue of ₹7,827.26 crore and net profit of ₹1,155.3 crore; however, net profit fell 22% YoY with EBITDA margins contracting to 26.1%.
- Segment performance: US business revenue of $317 million beat estimates, while domestic sales rose 14.7% YoY; US operations account for 39% of total sales.
- Brokerage stance: PL Capital and Prabhudas Lilladher maintain an 'Accumulate' rating with a ₹2,250 target, noting that peak margin benefits are eroding and competition is intensifying.
- Estimate revisions: PL Capital reduced FY28E and FY29E EPS estimates by 2-5%, reflecting anticipated PAT declines through FY26-28E.

- [Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-lupin-target-of-rs-2250-prabhudas-lilladher-14072553.html)
- [Broker’s Call: Lupin (Accumulate)](https://www.thehindubusinessline.com/markets/brokers-call-lupin-accumulate/article71669718.ece)
- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Stock market today: Sensex, Nifty cautious after rally; SBI, ITC gain](https://www.thehindubusinessline.com/markets/it-stocks-drag-nifty-even-as-fmcg-and-healthcare-hold-firm-fiis-buy-for-third-straight-session/article71663902.ece)
- [Lupin shares in focus after US sales beat expectations but profitability impacted](https://www.cnbctv18.com/market/lupin-share-price-q2-results-profit-falls-us-business-beats-estimate-20026525.htm)

### What Changed

Lupin Limited filed its Unaudited Financial Results for the quarter and half year ended September 30, 2026, with the NSE on November 5, 2026. This marks a shift from prior periods where such results were not yet reported in the available context. Concurrently, brokerages Prabhudas Lilladher and PL Capital have issued 'Accumulate' recommendations with a target price of ₹2,250. These views reflect expectations of declining Profit After Tax (PAT) over FY26-28E and increased competition for key products. Consequently, both brokers have cut their FY28E and FY29E EPS estimates by 2-5%, citing the wearing away of peak margin benefits.

- Filing Date: November 5, 2026 – Lupin submitted Unaudited Financial Results for the quarter and half year ended September 30, 2026, to the NSE.
- Brokerage Ratings: Prabhudas Lilladher and PL Capital maintain an 'Accumulate' rating with a target price of ₹2,250.
- Estimate Adjustments: Brokers reduced FY28E and FY29E EPS estimates by 2-5% due to expected PAT declines and erosion of peak margin benefits.

- [Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-lupin-target-of-rs-2250-prabhudas-lilladher-14072553.html)
- [Broker’s Call: Lupin (Accumulate)](https://www.thehindubusinessline.com/markets/brokers-call-lupin-accumulate/article71669718.ece)
- [Lupin Limited has informed the Exchange regarding copies of Newspaper Publication regarding Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Lupin2_05112026163455_SEintimationletter.pdf)

### Official Filings

Lupin Limited reported unaudited financial results for the half-year ended September 30, 2026, alongside significant corporate actions. The Group recorded consolidated revenue from operations of ₹279,580.3 million and net profit after tax of ₹53,554.7 million for the six-month period. For the quarter alone (Q2 FY2027), total revenue rose 11.1% year-over-year to INR 78,273 million; however, profitability metrics contracted, with EBITDA down 10.7% to INR 21,712 million, and profit after tax falling 22.2% to INR 14,848 million.

The Board approved several material transactions: an acquisition of VISUfarma B.V. for ₹20,902.7 million, a USD 90.0 million settlement with Astellas regarding Mirabegron ER Tablets, and a ₹3,162.8 million antitrust settlement. Lupin also launched Raltegravir Tablets USP, 600 mg in the U.S., claiming 180-day generic exclusivity eligibility with estimated annual sales of USD 26 million. Governance-wise, Mr. Akhil Gupta was appointed as an Additional Director (Non-Executive, Independent) effective November 3, 2026, for a five-year term. A final dividend of ₹18 per share (₹8,230.2 million) was disbursed in August 2026.

- H1 FY2027 Financials: Consolidated revenue of ₹279,580.3 million and PAT of ₹53,554.7 million; Q2 revenue grew 11.1% YoY to INR 78,273 million, but Q2 PAT declined 22.2% to INR 14,848 million.
- Major Settlements & Acquisitions: Board approved acquisition of VISUfarma B.V. for ₹20,902.7 million, a USD 90.0 million settlement with Astellas, and a ₹3,162.8 million antitrust settlement.
- Product Launch: Launched Raltegravir Tablets USP, 600 mg in the U.S. on November 3, 2026, with FDA approval and claimed 180-day exclusivity eligibility; estimated U.S. annual sales are USD 26 million.
- Governance & Dividends: Appointed Mr. Akhil Gupta as Independent Director for five years starting November 3, 2026; final dividend of ₹18 per share disbursed in August 2026.

- [Lupin Limited has informed the Exchange regarding copies of Newspaper Publication regarding Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Lupin2_05112026163455_SEintimationletter.pdf)
- [Lupin Limited has informed the Exchange about Link of Recording. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Lupin2_04112026210945_SE_Intimation_Audio_Link_Q2_FY27.pdf)
- [Lupin Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261104_212256965.xml)
- [Lupin Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Lupin2_03112026193332_SEletterpressrelease.pdf)
- [Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Lupin2_04112026004100_SE_Outcome_UFR_Intimation.pdf)
- [Lupin Limited has informed the Exchange regarding Change in Director(s) of the company. |SUBJECT: Change in Director(s)](https://nsearchives.nseindia.com/corporate/Lupin2_04112026011040_SE_Intimation_appointment_of_AG.pdf)
- [Lupin Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1988_WebXMLFile_20261104_012708850.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752379_04112026013259_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752380_04112026013306_WEB.xml)
- [Lupin Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Lupin Q2 FY2027 Results ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Lupin2_04112026014246_SE_Intimation_Press_Release_04112026.pdf)

### Fundamentals

Lupin’s operating trajectory shows strong top-line momentum with Sales reaching ₹27,958 crore in FY2026 (up from ₹22,708 crore in FY2025) and a TTM sales figure of ₹29,967 crore. However, the most recent quarterly results for Q2 FY2026-27 reveal a sequential slowdown: Revenue fell to ₹7,827 crore from ₹8,277 crore in Q1, accompanied by a drop in Net Profit to ₹1,155 crore from ₹1,417 crore. Despite this quarterly deceleration, long-term growth remains robust, evidenced by a 3-year compounded sales growth of 19% and profit growth of 140%. Earnings quality is a key strength; CFO/EBITDA conversion rebounded to 105% in Mar 2026 after dipping to 74% in Mar 2025, indicating effective working capital management as the Cash Conversion Cycle improved to 181 days. Financial health has strengthened significantly, with ROCE rising to 30% and cash reserves increasing to ₹1,939 crore as of Sep 2026. The primary risk lies in rising leverage, with Borrowings climbing to ₹6,616 crore in Mar 2026 and Interest costs jumping to ₹434 crore in FY2026.

- Sequential Quarterly Slowdown: Q2 FY2026-27 revenue decreased sequentially to ₹7,827 crore, with Net Profit falling to ₹1,155 crore, contrasting with strong annual growth trends.
- Earnings Quality Recovery: Cash flow conversion to operating profit improved sharply to 105% in FY2026, supported by a reduced Cash Conversion Cycle of 181 days.
- Leverage and Cost Pressure: Borrowings increased to ₹6,616 crore in FY2026, driving Interest expenses up to ₹434 crore, which impacts net margins despite high ROCE of 30%.
- Balance Sheet Expansion: Total assets grew to ₹39,911 crore as of Sep 2026, with Trade Payables rising to ₹4,558 crore, reflecting scaling operations.

### Bull Case

Lupin presents a conditional upside case anchored by strong top-line execution and sectoral tailwinds, despite near-term margin pressures. In Q2 FY27, the company delivered revenue of ₹7,827.26 crore and net profit of ₹1,155.3 crore, both marginally ahead of market estimates. The US business, contributing 39% of sales, generated $317 million in revenue, beating expectations, while domestic sales grew 14.7% year-on-year. This operational strength is supported by a broader pharmaceutical sector rally in 2026, where the sectoral index rose 27% year-to-date on resilient demand and improving margins. Technically, the stock trades at ₹1,988.10, showing resilience with support at ₹1,986.54 and resistance at ₹2,007.10. While the daily trend is bearish, the monthly supertrend remains bullish, suggesting longer-term structural support. Analysts maintain an 'Accumulate' rating with a target of ₹2,250, citing predictable earnings recovery even as they note potential EPS declines due to competition.

- Q2 FY27 revenue of ₹7,827.26 crore and net profit of ₹1,155.3 crore beat market estimates, driven by a $317 million US business performance and 14.7% domestic sales growth.
- The Indian pharmaceutical sector led equity returns in 2026 with a 27% year-to-date rise, providing a favorable macro backdrop for Lupin's earnings recovery.
- Monthly technical indicators show a bullish supertrend direction, contrasting with daily bearish signals, indicating underlying long-term support around the current price of ₹1,988.10.
- Brokerages maintain an 'Accumulate' consensus with a ₹2,250 target, acknowledging that while peak margin benefits are wearing off, the top-line trajectory remains robust.

- [Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-lupin-target-of-rs-2250-prabhudas-lilladher-14072553.html)
- [Broker’s Call: Lupin (Accumulate)](https://www.thehindubusinessline.com/markets/brokers-call-lupin-accumulate/article71669718.ece)
- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Stock market today: Sensex, Nifty cautious after rally; SBI, ITC gain](https://www.thehindubusinessline.com/markets/it-stocks-drag-nifty-even-as-fmcg-and-healthcare-hold-firm-fiis-buy-for-third-straight-session/article71663902.ece)
- [Lupin shares in focus after US sales beat expectations but profitability impacted](https://www.cnbctv18.com/market/lupin-share-price-q2-results-profit-falls-us-business-beats-estimate-20026525.htm)
- [Lupin Limited has informed the Exchange regarding copies of Newspaper Publication regarding Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Lupin2_05112026163455_SEintimationletter.pdf)
- [Lupin Limited has informed the Exchange about Link of Recording. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Lupin2_04112026210945_SE_Intimation_Audio_Link_Q2_FY27.pdf)
- [Lupin Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261104_212256965.xml)
- [Lupin Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Lupin2_03112026193332_SEletterpressrelease.pdf)
- [Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Lupin2_04112026004100_SE_Outcome_UFR_Intimation.pdf)

### Bear Case

Lupin faces near-term operational and technical headwinds despite recent top-line resilience. In Q2 FY27, profitability contracted sharply by 22% year-on-year as EBITDA margins fell to 26.1%, driven by margin erosion in its largest market, the US, which contributed 39% of sales. Brokerage estimates reinforce this caution; PL Capital has cut FY28E and FY29E EPS projections by 2-5%, citing the wearing away of peak margin benefits and increased competition for key products. Technically, the stock is under pressure, trading at ₹1,988.10 with a daily Supertrend signal indicating a bearish trend. The share price has declined 18.6% over the past six months and sits in a 20.9% drawdown from its peak, with resistance clustered tightly above at ₹2,007.10.

- Profitability dropped 22% YoY in Q2 FY27 with EBITDA margins contracting to 26.1%, offsetting revenue growth.
- PL Capital reduced FY28E and FY29E EPS estimates by 2-5%, citing margin erosion and competitive pressures.
- The stock trades in a bearish daily trend (Supertrend) with a 20.9% current drawdown and -18.6% return over six months.
- Resistance is immediate at ₹2,007.10, limiting upside momentum near the ₹1,988 level.

- [Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-lupin-target-of-rs-2250-prabhudas-lilladher-14072553.html)
- [Broker’s Call: Lupin (Accumulate)](https://www.thehindubusinessline.com/markets/brokers-call-lupin-accumulate/article71669718.ece)
- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Stock market today: Sensex, Nifty cautious after rally; SBI, ITC gain](https://www.thehindubusinessline.com/markets/it-stocks-drag-nifty-even-as-fmcg-and-healthcare-hold-firm-fiis-buy-for-third-straight-session/article71663902.ece)
- [Lupin shares in focus after US sales beat expectations but profitability impacted](https://www.cnbctv18.com/market/lupin-share-price-q2-results-profit-falls-us-business-beats-estimate-20026525.htm)
- [Lupin Limited has informed the Exchange regarding copies of Newspaper Publication regarding Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Lupin2_05112026163455_SEintimationletter.pdf)
- [Lupin Limited has informed the Exchange about Link of Recording. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Lupin2_04112026210945_SE_Intimation_Audio_Link_Q2_FY27.pdf)
- [Lupin Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261104_212256965.xml)
- [Lupin Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Lupin2_03112026193332_SEletterpressrelease.pdf)
- [Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Lupin2_04112026004100_SE_Outcome_UFR_Intimation.pdf)

### FAQs

**How did Lupin perform in Q2 FY27, and what were the key financial drivers?**

For the quarter ended September 30, 2026, Lupin reported consolidated revenue of ₹7,827.26 crore and net profit of ₹1,155.3 crore. While top-line growth was supported by a 14.7% rise in domestic sales and US revenue of $317 million, profitability declined 22% year-on-year due to an EBITDA margin contraction to 26.1%. The results were marginally ahead of market estimates.

**What recent corporate actions and settlements impacted Lupin's half-year results?**

In the six months ended September 30, 2026, Lupin recorded a net profit of ₹53,554.7 million on revenue of ₹279,580.3 million. Key events included the acquisition of VISUfarma B.V. for ₹20,902.7 million, a USD 90.0 million settlement with Astellas regarding Mirabegron ER Tablets, and an antitrust settlement of ₹3,162.8 million. A final dividend of ₹18 per share was disbursed in August 2026.

**What is the current technical trend and price level for Lupin shares?**

As of November 6, 2026, Lupin’s daily technical trend is bearish, with the stock closing at ₹1,988.10. The monthly trend remains bullish. Immediate resistance is noted at ₹2,007.10 (0.96% above), while support lies near ₹1,986.54. The stock has experienced a maximum drawdown of -23.6% and is currently down -15.9% since the start of the tracking period.

- [Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/accumulate-lupin-target-of-rs-2250-prabhudas-lilladher-14072553.html)
- [Broker’s Call: Lupin (Accumulate)](https://www.thehindubusinessline.com/markets/brokers-call-lupin-accumulate/article71669718.ece)
- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Stock market today: Sensex, Nifty cautious after rally; SBI, ITC gain](https://www.thehindubusinessline.com/markets/it-stocks-drag-nifty-even-as-fmcg-and-healthcare-hold-firm-fiis-buy-for-third-straight-session/article71663902.ece)
- [Lupin shares in focus after US sales beat expectations but profitability impacted](https://www.cnbctv18.com/market/lupin-share-price-q2-results-profit-falls-us-business-beats-estimate-20026525.htm)
- [Lupin Limited has informed the Exchange regarding copies of Newspaper Publication regarding Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/Lupin2_05112026163455_SEintimationletter.pdf)
- [Lupin Limited has informed the Exchange about Link of Recording. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Lupin2_04112026210945_SE_Intimation_Audio_Link_Q2_FY27.pdf)
- [Lupin Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261104_212256965.xml)
- [Lupin Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Lupin2_03112026193332_SEletterpressrelease.pdf)
- [Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Lupin2_04112026004100_SE_Outcome_UFR_Intimation.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Downtrend
- Pivot point: ₹1,975.6
- Risk regime: Price Risk Requires Attention

### Support levels
- 1986.5382568359375
- 1920.9703125
- 1893.2796875

### Resistance levels
- 2031.75
- 2130.6609375
- 2161.7749999999996

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.01% |
| return_10 | +3.07% |
| return_1m | -2.03% |
| return_1y | +1.67% |
| return_20 | +2.64% |
| return_3m | -16.64% |
| return_5 | -1.14% |
| return_6m | -18.62% |
| return_since_start | -15.93% |
| return_ytd | -5.45% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -23.57% |
| annualized_volatility | +23.71% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Lupin Limited Q2 FY2026-27: Profit falls as revenue retreats from Q1 peak

Lupin’s Q2 FY2026-27 revenue from operations declined 5.4% sequentially to ₹7,827 crore, while profit before tax fell 21.7% to ₹1,580 crore as expenses remained broadly flat. Year on year, revenue rose 11.1%, but profit before tax declined 21.3% and profit for the period fell 22.2% to ₹1,155 crore. Lower tax expense partly cushioned the sequential earnings decline.

## Revenue eased sequentially but grew year on year

Revenue from operations fell from ₹8,277 crore in Q1 FY2026-27 to ₹7,827 crore in Q2, a 5.4% decline. It was up 11.1% from ₹7,048 crore in Q2 FY2025-26. Revenue also remained above the ₹7,168 crore recorded in Q3 FY2025-26 and ₹7,475 crore in Q4 FY2025-26, though below the Q1 peak in this recent sequence.

Total income declined 5.4% sequentially to ₹7,954 crore from ₹8,407 crore in Q1. Other income was ₹127 crore in Q2.

## Flat expenses amplified the sequential profit decline

Expenses were ₹6,374 crore in Q2, down just 0.2% from ₹6,390 crore in Q1. Profit before tax fell 21.7% sequentially to ₹1,580 crore from ₹2,017 crore. It was also 21.3% lower than the ₹2,007 crore reported in Q2 FY2025-26.

Q2 expense lines included employee benefit expense of ₹1,424 crore, materials consumed of ₹1,311 crore, stock-in-trade purchases of ₹733 crore and depreciation and amortisation of ₹486 crore.

## Lower tax expense partly cushioned the fall in profit

Tax expense declined to ₹424 crore from ₹600 crore in Q1. Current tax was ₹72 crore, compared with ₹984 crore in Q1, while deferred tax was a charge of ₹352 crore, versus a credit of ₹384 crore in Q1. Finance costs eased to ₹106 crore from ₹110 crore.

Profit for the period was ₹1,155 crore, down 18.5% sequentially from ₹1,417 crore and 22.2% year on year from ₹1,485 crore. Basic EPS was ₹25.27 and diluted EPS ₹25.14, compared with ₹30.95 and ₹30.89, respectively, in Q1. Trailing 12-month EPS was ₹113.92.

## Operating cash flow was positive; free cash flow was negative

Cash flow from operating activities was ₹2,906 crore in Q2, while investing activities used ₹3,183 crore. Reported free cash flow was negative ₹276 crore, and financing activities used ₹1,952 crore. Cash and cash equivalents stood at ₹1,939 crore on 30 September 2026, compared with ₹4,168 crore on 31 March 2026.

## Assets and intangible balances increased

Total assets rose to ₹39,911 crore on 30 September 2026 from ₹38,365 crore on 31 March 2026 and ₹33,500 crore on 30 September 2025. Goodwill increased to ₹3,368 crore from ₹2,659 crore at March-end, while other intangible assets rose to ₹4,176 crore from ₹2,886 crore. Intangible assets under development were ₹397 crore, and capital work in progress was ₹931 crore, up from ₹695 crore at March-end.

Equity increased to ₹24,051 crore from ₹22,513 crore at 31 March 2026. Borrowings totalled ₹5,496 crore at 30 September, comprising ₹4,154 crore current and ₹1,342 crore non-current.

## Inventory and receivables edged higher from March

At 30 September 2026, inventories stood at ₹6,563 crore and trade receivables at ₹6,656 crore, compared with ₹6,083 crore and ₹6,604 crore, respectively, at 31 March. Trade payables increased to ₹4,558 crore from ₹4,173 crore. Current assets were ₹23,070 crore and current liabilities ₹12,541 crore at September-end.

## Key Takeaway

Q2 brought a sequential pullback in revenue and a sharper decline in profit before tax, as expenses barely changed from Q1. Year-on-year revenue growth did not prevent lower earnings, while lower tax expense moderated the sequential fall in profit for the period. Positive operating cash flow was offset by investing outflows, leaving free cash flow negative.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +46.85%
- FII holding: +22.42%
- DII holding: +24.65%
- Mutual fund holding: +14.84%
- Retail holding: +4.92%
- Promoter pledged: +0.00%

### Major reported shareholders

- Lupin Investments Private Limited — +45.31% (Bodies Corporate)
- Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund — +4.37%
- Life Insurance Corporation Of India — +4.09%
- Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I — +2.75%
- Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund — +2.60%
- Sbi Elss Tax Saver Fund — +1.96%
- Mirae Asset Large & Midcap Fund — +1.74%
- Hdfc Life Insurance Company Limited — +1.10%
- Manju D Gupta — +0.85%
- Nilesh Gupta — +0.20%

## Official filings

- 2026-11-07 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261107_094316637.xml)
- 2026-11-06 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_06112026203743_SE_Intimation_of_Investor_Meet_Transcript.pdf)
- 2026-11-05 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_05112026163455_SEintimationletter.pdf)
- 2026-11-04 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04112026210945_SE_Intimation_Audio_Link_Q2_FY27.pdf)
- 2026-11-04 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261104_212256965.xml)
- 2026-11-03 — Press Release: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_03112026193332_SEletterpressrelease.pdf)
- 2026-11-03 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04112026004100_SE_Outcome_UFR_Intimation.pdf)
- 2026-11-03 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04112026011040_SE_Intimation_appointment_of_AG.pdf)
- 2026-11-03 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1988_WebXMLFile_20261104_012708850.xml)
- 2026-11-03 — Financial Results Filing: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752379_04112026013259_WEB.xml)
- 2026-11-03 — Financial Results Filing: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752380_04112026013306_WEB.xml)
- 2026-11-03 — Press Release: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04112026014246_SE_Intimation_Press_Release_04112026.pdf)
- 2026-11-03 — Earnings Presentation: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04112026014841_SE_Intimation_Investor_Presentation_04112026.pdf)
- 2026-11-02 — Press Release: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_02112026175800_SELetterPressRelease.pdf)
- 2026-10-24 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_24102026141953_SEintimation_Goa_24102026.pdf)
- 2026-10-23 — Press Release: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_23102026095748_SELetterPressRelease.pdf)
- 2026-10-23 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_23102026163628_NSEBSEINTIMATION_signed_.pdf)
- 2026-10-23 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_1988_WebXMLFile_20261023_163830680.xml)
- 2026-10-22 — Management Change: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_22102026222223_SE_Intimation_Appointment_of_Brian_Savage.pdf)
- 2026-10-22 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1988_WebXMLFile_20261022_223525444.xml)
- 2026-10-19 — Board Meeting Notice: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_19102026160749_Board_Meeting_Intimation.pdf)
- 2026-10-19 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_19102026162709_SE_Intimation_Earnings_Call_Q2_FY27.pdf)
- 2026-10-19 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1988_WebXMLFile_20261019_163904615.xml)
- 2026-10-19 — Board Meeting Notice: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1988_WebXMLFile_20261019_163904615.xml)
- 2026-10-19 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20261019_164502895.xml)

## News and market events

- 2026-11-06 — MONEYCONTROL: **Accumulate Lupin; target of Rs 2250: Prabhudas Lilladher** — Prabhudas Lilladher has issued an 'Accumulate' recommendation for Lupin with a target price of Rs 2,250. The brokerage's view is presented in the context of stock market news coverage. — [Source](https://www.moneycontrol.com/news/business/stocks/accumulate-lupin-target-of-rs-2250-prabhudas-lilladher-14072553.html)
- 2026-11-05 — The Hindu: **Broker’s Call: Lupin (Accumulate)** — PL Capital has maintained an 'Accumulate' rating on Lupin with a target price of ₹2,250, citing expected declines in PAT over FY26-28E and increased competition for key products. The broker cut its FY28E and FY29E EPS estimates by 2-5% due to wearing away of peak margin benefits. — [Source](https://www.thehindubusinessline.com/markets/brokers-call-lupin-accumulate/article71669718.ece)
- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-11-04 — The Hindu: **Stock market today: Sensex, Nifty cautious after rally; SBI, ITC gain** — Indian markets opened cautiously on November 4, with the Sensex and Nifty trading slightly higher after a sharp four-session rally, as technology stocks dragged performance while banking and FMCG sectors gained. Continued foreign institutional investor buying supported sentiment, contrasting with domestic institutional selling, amid global pressures from US midterm election outcomes and mixed economic data. Analysts suggest near-term consolidation with a buy-on-dips strategy, citing easing crude prices and rotation into consumption and healthcare, while warning of potential profit-booking risk — [Source](https://www.thehindubusinessline.com/markets/it-stocks-drag-nifty-even-as-fmcg-and-healthcare-hold-firm-fiis-buy-for-third-straight-session/article71663902.ece)
- 2026-11-04 — CNBC-TV18: **Lupin shares in focus after US sales beat expectations but profitability impacted** — Lupin Ltd. reported Q2 FY27 revenue of ₹7,827.26 crore and net profit of ₹1,155.3 crore, figures that were marginally ahead of market estimates despite a 22% year-on-year decline in profitability driven by an EBITDA margin contraction to 26.1%. The pharmaceutical company's US business, its largest market contributing 39% of sales, beat expectations with $317 million in revenue, while domestic sales rose 14.7% year-on-year. Lupin shares closed 0.97% higher following the results, which highlighted strong top-line growth offsetting sequential declines in earnings. — [Source](https://www.cnbctv18.com/market/lupin-share-price-q2-results-profit-falls-us-business-beats-estimate-20026525.htm)
- 2026-11-04 — BUSINESSTODAY: **GIFT Nifty down 93 pts; NSE, Lupin, CleanMax, Cocord Biotech, MK Sons among top stocks in focus** — Indian equity markets are expected to open cautiously as traders assess signals from US mid-term elections and crude oil movements, with GIFT Nifty futures indicating a weak start. Key stocks in focus include the National Stock Exchange of India, which reported a 23% year-on-year jump in net profit for the September quarter, and Lupin, which received FDA approval for Raltegravir Tablets in the US. — [Source](https://www.businesstoday.in/markets/trending-stocks/story/gift-nifty-down-93-pts-nse-lupin-cleanmax-cocord-biotech-mk-sons-among-top-stocks-in-focus-565549-2026-11-04)
- 2026-11-04 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Nuvama Wealth Management (₹1,866) – BUY** — Lupin reported a 22.19% decline in its Q2 net profit to ₹1,155.3 crore, driven by revenue growth and adjustments related to US settlements. The article also highlights Nuvama Wealth Management as a stock recommendation with a 'BUY' rating. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-4th-november-2026/article71661036.ece)
- 2026-11-04 — The Hindu: **Lupin Q2 net profit falls 22.19% to ₹1,155.3 crore** — Lupin reported a 22.19% decline in Q2 consolidated net profit to ₹1,155.30 crore, primarily due to an exceptional item related to a US antitrust settlement. The company's revenue from operations rose to ₹7,827.26 crore during the quarter, while its US subsidiary settled an antitrust matter for ₹316.28 crore without admission of liability. — [Source](https://www.thehindubusinessline.com/companies/lupin-q2-net-profit-falls-2219-to-11553-crore/article71663691.ece)
- 2026-11-03 — Mint: **Lupin Q2 net profit falls 22.19 pc to ₹1,155.3 crore | Mint** — Lupin reported a 22.19% decline in Q2 consolidated net profit to ₹1,155.3 crore, primarily due to an exceptional item related to a ₹316.28 crore settlement of an antitrust matter in the US without admission of liability. Despite the profit drop, revenue from operations rose 11.07% to ₹7,827.26 crore, driven by a 9.3% increase in US sales and a 14.7% rise in India sales. The company remains the third-largest pharmaceutical player in the US generic market by prescriptions as per IQVIA data for September 2026. — [Source](https://www.livemint.com/focus/lupin-q2-net-profit-falls-22-19-pc-to-rs-1-155-3-crore-11793739442753.html)
- 2026-11-03 — CNBC-TV18: **Lupin launches HIV drug in US, secures eligibility for 180-day generic exclusivity** — Lupin has launched Raltegravir Tablets USP, 600 mg, in the US following FDA approval, securing eligibility for 180-day generic exclusivity as the exclusive first-to-file applicant. The drug, which is bioequivalent to Merck's Isentress HD and had estimated annual US sales of $26 million as of September 2026, treats HIV infection in adults and pediatric patients weighing at least 40 kg. This launch follows recent FDA approvals for Lupin's Amifampridine Tablets and sodium zirconium cyclosilicate. — [Source](https://www.cnbctv18.com/market/stocks/lupin-share-price-launches-hiv-drug-in-us-secures-eligibility-for-180-day-generic-exclusivity-20026382.htm)
- 2026-11-03 — BUSINESSTODAY: **GIFT Nifty up 120 pts; ITC, Lupin, Nalco, BLS Polymers, NBCC, SFC Enviro among top stocks in focus** — ITC reported declining profits and margins due to steep tax hikes on cigarettes, while NBCC signed an MoU with the Government of Bihar for redevelopment projects. Lupin received USFDA approval for a generic drug application. — [Source](https://www.businesstoday.in/markets/stocks/story/gift-nifty-up-120-pts-itc-lupin-nalco-bls-polymers-nbcc-sfc-enviro-among-top-stocks-in-focus-565280-2026-11-03)
- 2026-11-03 — The Hindu: **Stocks to watch, Nov 3: GRSE, Dr Reddy’s, Lupin, NBCC, HPCL and others bag major orders, approvals** — Garden Reach Shipbuilders & Engineers Ltd. secured a ₹32,000-crore contract from the Indian Navy for five corvettes, while Dr Reddy’s Laboratories Ltd and Lupin Limited received USFDA approvals for key drugs. Additionally, NBCC (India) Limited obtained ₹70.50 crore in orders from Oil India Ltd and HAL, Belrise Industries Ltd partnered with Yamato Co Ltd for filtration technology, and Datakosa Ltd won a $2.46-million AI automation order from Hermes Networks Inc. — [Source](https://www.thehindubusinessline.com/markets/buzzing-stocks-grse-dr-reddys-lupin-nbcc-hpcl-belrise-and-datakosa-in-focus/article71659200.ece)
- 2026-11-02 — CNBC-TV18: **Stocks to Watch for November 3: ITC, Marico, CONCOR, Petronet LNG and more** — Investors are focusing on companies reporting September-quarter earnings, including Petronet LNG, Marico, CONCOR, Granules India, PTC India, and GSFC, alongside IDBI Bank amid a nationwide employee strike against its proposed stake sale. Key results show mixed performance, with Petronet LNG and Marico posting profit growth while PTC India and GSFC reported significant declines in net profit. Other notable developments include Lupin receiving US FDA approval for Amifampridine Tablets and Balaji Amines reporting a sharp increase in quarterly profits. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-november-3-itc-marico-concor-petronet-lng-and-more-20025147.htm)
- 2026-11-02 — CNBC-TV18: **Lupin gets USFDA nod for amifampridine tablets, eligible for 180-day generic exclusivity** — Lupin Ltd has received USFDA approval for its Amifampridine Tablets, 10 mg, which are bioequivalent to Catalyst Pharmaceuticals' Firdapse and qualify the company for 180 days of shared generic exclusivity. This regulatory milestone follows recent approvals for Phytonadione Injectable Emulsion and Modafinil tablets, underscoring continued progress in the company's US portfolio. Despite these developments, Lupin shares declined by 0.62% on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/lupin-share-price-gets-usfda-nod-for-amifampridine-tablets-eligible-for-180-day-generic-exclusivity-20025297.htm)
- 2026-11-02 — MONEYCONTROL: **Lupin's 16% slide since Q1 results may have priced in margin pressure; Nomura retains 'Buy' ahead of Q2** — Nomura has retained a 'Buy' rating on Lupin, suggesting that the stock's 16% decline since its Q1 results may have already priced in margin pressure. This assessment comes ahead of the company's upcoming Q2 earnings release. — [Source](https://www.moneycontrol.com/news/business/stocks/lupin-s-16-slide-since-q1-results-may-have-priced-in-margin-pressure-nomura-retains-buy-ahead-of-q2-14066468.html)
- 2026-10-27 — BUSINESSTODAY: **Lupin’s global ambitions rest on innovation and specialty medicines** — Building a global pharmaceutical company often requires a willingness to make decisions whose results may not be immediately visible. — [Source](https://www.businesstoday.in/magazine/profile/story/lupins-global-ambitions-rest-on-innovation-and-specialty-medicines-564100-2026-10-27)
- 2026-10-26 — BUSINESSTODAY: **GIFT Nifty up 33 points; Infosys, Kotak Bank, TMCV, IndusInd Bank, Vedanta among top stocks in focus** — Indian equity markets are set for a positive but cautious start to the new week on Friday amid mixed global sentiments and elevated crude oil prices. — [Source](https://www.businesstoday.in/markets/trending-stocks/story/gift-nifty-up-33-points-infosys-kotak-bank-tmcv-indusind-bank-vedanta-among-top-stocks-in-focus-563529-2026-10-26)
- 2026-10-26 — The Hindu: **Stocks to watch, Oct 26: Raymond, RailTel, KEC Intl, Honasa, BL Kashyap, Lupin, Orchid Pharma, Gland Pharma among 15 stocks to remain in focus** — Markets in focus: a mix of M&A, contract wins, regulatory updates and new product launches across 15 stocks, from Ray­mond’s rebrand to Lupin’s FDA observation and Orchid Pharma’s Latin American licensing deal. — [Source](https://www.thehindubusinessline.com/markets/stocks-to-watch-oct-26-raymond-railtel-kec-intl-honasa-bl-kashyap-lupin-orchid-pharma-gland-pharma-among-15-stocks-to-remain-in-focus/article71624286.ece)
- 2026-10-25 — CNBC-TV18: **Stocks to Watch for October 26: RIL, Infosys, BPCL, Kotak Mahindra Bank, Torrent Pharma and more** — From Infosys’ revised FY27 revenue growth guidance to BPCL’s profit recovery and Reliance Industries' Jio Platforms’ record IPO demand, here are the stocks to track in Monday’s trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-october-26-reliance-industries-infosys-bpcl-kotak-mahindra-bank-torrent-pharma-share-price-20018298.htm)
- 2026-10-25 — The Hindu: **USFDA concludes inspection at Lupin's Goa facility with one observation** — USFDA inspection at Lupin's Goa facility ends with one observation, prompt corrective action planned by the company. — [Source](https://www.thehindubusinessline.com/companies/usfda-concludes-inspection-at-lupins-goa-facility-with-one-observation/article71622511.ece)
- 2026-10-24 — MONEYCONTROL: **USFDA concludes inspection at Lupin's Goa facility with one observation** — USFDA concludes inspection at Lupin's Goa facility with one observation Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Tonbo Imaging share price UP Elections iPhone Duo Elon Musk Annamalai Piyush Goyal Donald Trump Sonam Wangchuk News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Gold MCX Price Personal Finance more Home Loans up to 50 Lakhs Credit Cards Lif — [Source](https://www.moneycontrol.com/news/business/usfda-concludes-inspection-at-lupin-s-goa-facility-with-one-observation-14059258.html)
- 2026-10-23 — The Hindu: **Lupin appoints Brian Savage as President, Chief Legal Officer** — Lupin names Brian Savage as President and Chief Legal Officer, leveraging his Teva leadership to strengthen governance and IP globally. — [Source](https://www.thehindubusinessline.com/companies/lupin-appoints-brian-savage-as-president-chief-legal-officer/article71614844.ece)
- 2026-10-22 — MONEYCONTROL: **Sustainability has become a critical driver of business resilience and long-term value creation at Lupin, says Ramesh Swaminathan** — Sustainability has become a critical driver of business resilience and long-term value creation at Lupin, says Ramesh Swaminathan Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio IPO Annamalai DeepSeek Indian Rupee Priyanka Gandhi Marco Rubio Abhijeet Dipke 8th CPC Fitment Factor Kiren Rijiju News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX Price Gold MCX Price Person — [Source](https://www.moneycontrol.com/news/business/sustainability-has-become-a-critical-driver-of-business-resilience-and-long-term-value-creation-at-lupin-says-ramesh-swaminathan-14057870.html)
- 2026-10-19 — Economic Times: **Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players** — India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/indias-pharmaceutical-companies-to-report-mixed-results-as-domestic-growth-offsets-pricing-pressures/articleshow/135037267.cms)
- 2026-10-08 — CNBC-TV18: **Lupin gets US FDA nod for vitamin K injection with $52 million US market** — Lupin has received US FDA approval for a prefilled vitamin K injection used to treat low blood clotting and vitamin K deficiency, with $52.3 million in annual US sales. — [Source](https://www.cnbctv18.com/market/lupin-gets-us-fda-nod-for-vitamin-k-injection-with-52-million-us-market-20008050.htm)

## Business profile

**Strategic vision:** Develops and delivers pharmaceutical solutions globally.

### Business segments
- **Global Generics:** Focuses on providing accessible and affordable generic medicines across developed markets, with a significant presence in the U.S.
- **Emerging Markets:** Delivers accessible and high-quality healthcare solutions tailored to the unique healthcare landscapes of emerging markets.
- **India Business:** Features a diversified product portfolio across major therapy areas within India, including anti-tuberculosis, anti-diabetes, respiratory, and cardiology.
- **Specialty and Innovation:** Driven by science-led innovations, particularly in complex platforms such as inhalation and injectable technologies, to address unmet medical needs.
- **Biosimilars:** Aims to make complex biologics more accessible and affordable through in-depth research and quality-led manufacturing processes.
- **Our Adjacencies:** Engages in patient-centric initiatives that extend beyond medication to offer holistic healthcare support.

### Competitive strengths
- Global network of operations and personnel.
- Integrated manufacturing, procurement, and supply chain functions.
- Commitment to quality and compliance in all stages of operation.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/lupin
Markdown representation: https://faxioms.com/stocks/lupin?render=md